ArticleClinical cancer research : an official journal of the American Association for Cancer Research2012
Intracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 58 citations in OpenAlex.
- Preparation of human serum albumin-doxorubicin modified carbon nanotubes mediated combined photothermal and chemotherapeutic strategies in melanoma application.Journal of materials science. Materials in medicine · 2025Article
- Current advance of nanotechnology in diagnosis and treatment for malignant tumors.Signal transduction and targeted therapy · 2024Review
- The Role of Microglia in Brain Metastases: Mechanisms and Strategies.Aging and disease · 2024Review
- Nanotube breakthroughs: unveiling the potential of carbon nanotubes as a dual therapeutic arsenal for Alzheimer's disease and brain tumors.Frontiers in oncology · 2023Review
- Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms.Frontiers in bioengineering and biotechnology · 2023Review
- Natural and synthetic nanovectors for cancer therapy.Nanotheranostics · 2023Review
- Review
- Utilization of metal or non-metal-based functional materials as efficient composites in cancer therapies.RSC advances · 2022Review
- The Landscape of Nanovectors for Modulation in Cancer Immunotherapy.Pharmaceutics · 2022Review
- Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Intratumorally CpG immunotherapy with carbon nanotubes inhibits local tumor growth and liver metastasis by suppressing the epithelial-mesenchymal transition of colon cancer cells.Anti-cancer drugs · 2021Article
- Nonsurgical treatment of skin cancer with local delivery of bioadhesive nanoparticles.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Modulating the Tumour Microenvironment by Intratumoural Injection of Pattern Recognition Receptor Agonists.Cancers · 2020Review
- Prophylactic TLR9 stimulation reduces brain metastasis through microglia activation.PLoS biology · 2019Article
- High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme.ACS nano · 2019Article
- S100B suppression alters polarization of infiltrating myeloid-derived cells in gliomas and inhibits tumor growth.Cancer letters · 2018Article
- Biomaterials for vaccine-based cancer immunotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2018Review
- Immunostimulatory CpG on Carbon Nanotubes Selectively Inhibits Migration of Brain Tumor Cells.Bioconjugate chemistry · 2018Article
- Nanomedicine Strategies to Target Tumor-Associated Macrophages.International journal of molecular sciences · 2017Review
- Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
Abstract
purposeRecently, we showed that intratumoral delivery of low-dose, immunostimulatory CpG oligodeoxynucleotides conjugated with carbon nanotubes (CNT-CpG) was more effective than free CpG and not only eradicated intracranial (i.c.) gliomas but also induced antitumor immunity that protected mice from subsequent i.c. or systemic tumor rechallenge. Here, we examined whether the same "intracerebral immunotherapy" strategy could be applied to the treatment of metastatic brain tumors. EXPERIMENTAL
designMice with both i.c. and s.c. melanomas were injected intratumorally with CNT-CpG into either location. Antitumor responses were assessed by flow cytometry, bioluminescent imaging, and animal survival.
resultsWhen given s.c., CNT-CpG response was mostly local, and it only modestly inhibited the growth of i.c. melanomas. However, i.c. CNT-CpG abrogated the growth of not only brain but also s.c. tumors. Furthermore, compared with s.c. injections, i.c. CNT-CpG elicited a stronger inflammatory response that resulted in more potent antitumor cytotoxicity and improved in vivo trafficking of effector cells into both i.c. and s.c. tumors. To investigate factors that accounted for these observations, CNT-CpG biodistribution and cellular inflammatory responses were examined in both tumor locations. Intracranial melanomas retained the CNT-CpG particles longer and were infiltrated by Toll-like receptor (TLR-9)-positive microglia. In contrast, myeloid-derived suppressive cells were more abundant in s.c. tumors. Although depletion of these cells before s.c. CNT-CpG therapy enhanced its cytotoxic responses, antitumor responses to brain melanomas were unchanged.
conclusionsThese findings suggest that intracerebral CNT-CpG immunotherapy is more effective than systemic therapy in generating antitumor responses that target both brain and systemic melanomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.